Prm160 - Impact of Post-Progression Olaratumab (Olara) Monotherapy Following Doxorubicin (Dox) Monotherapy on Overall Survival (Os).

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2280
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

1-Antitrypsin Monotherapy Prolongs Islet Allograft Survival in Mice

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2005English

Impact of National Guidelines on Brachytherapy Monotherapy Practice Patterns for Prostate Cancer

Cancer
Cancer ResearchOncology
2013English

SAT0058 Effects of Baricitinib on Patients Who Stop Methotrexate Monotherapy and Switch to Baricitinib Monotherapy

2017English

Prm155 - Joint Modeling of Overall Survival and Progression Free Survival

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Treatment Outcome of Irinotecan Monotherapy

Japanese Journal of Lung Cancer
OncologyRespiratory MedicinePulmonary
2003English

Multivariate Network Meta-Analysis of Progression Free Survival and Overall Survival

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Efficacy and Safety of Switching Latanoprost Monotherapy to Bimatoprost Monotherapy or Combination of Brinzolamide and Latanoprost

Open Ophthalmology Journal
Ophthalmology
2016English

Appropriate Conversion From Valproate Monotherapy to Lamotrigine Monotherapy in Japanese Women With Epilepsy

Epilepsy and Seizure
Neurology
2016English

The Clinical Impact of the Post-Progression Survival on the Overall Survival in Elderly Patients or Those With a Poor Performance Status and Extensive-Disease Small-Cell Lung Cancer

Japanese Journal of Lung Cancer
OncologyRespiratory MedicinePulmonary
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy